EMA Authorised: Mimpara (cinacalcet hydrochloride) — Amgen Europe B.V.

View source ↗

Summary

The European Medicines Agency authorised Mimpara (cinacalcet hydrochloride) for indications including hypercalcemia, parathyroid neoplasms, and hyperparathyroid…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypercalcemia
• Hyperparathyroidism
• Parathyroid Neoplasms

Drugs mentioned

• Mimpara (cinacalcet hydrochloride)

Snippet

Status: Authorised. Therapeutic area: Hypercalcemia;Parathyroid Neoplasms;Hyperparathyroidism. MAH: Amgen Europe B.V.. Decision date: 03/06/2024